Subcutaneous administration starting with the first dose

Patients can receive DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) subcutaneously for faster administration compared with DARZALEX® (daratumumab), starting with their very first dose. DARZALEX FASPRO® is a fixed dose, and comes in a ready-to-use, single-dose vial, which means no weight-based calculations and no dilution needed.1,2*

DARZALEX FASPRO® contains 30,000 units of recombinant hyaluronidase1:

  • Increases permeability of subcutaneous tissue
  • Enables 15 mL containing 1,800 mg of daratumumab to be absorbed into the subcutaneous tissue of the abdomen

When administering DARZALEX FASPRO®, it’s important to use an appropriate needle gauge. In the clinical trials, 23- to 25-gauge needles were used for the injection.1,3

DARZALEX FASPRO® is for subcutaneous use only. DARZALEX FASPRO® has different dosage and administration instructions than DARZALEX®. Do not administer intravenously.1,2

Pre-medication1

Pre-medicate patients 1 to 3 hours before each dose with a histamine-1 receptor antagonist, acetaminophen, and a corticosteroid.

~3 to 5 minute injection1

icon-time

Post-medication1

Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions* (ARRs).

Monitor patients for systemic ARRs, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) ARRs, immediately and permanently discontinue DARZALEX FASPRO®.1

*DARZALEX® is administered by intravenous infusion over approximately 7, 4, and 3 hours for the first, second, and subsequent infusions, respectively. DARZALEX FASPRO® is administered by subcutaneous injection in ~3 to 5 minutes.1,2

In clinical trials of DARZALEX FASPRO® and DARZALEX®, and the Prescribing Information for DARZALEX®, the terms "infusion reactions" and "infusion-related reactions" were used instead of "systemic administration-related reactions."